Avacta Group (LON:AVCT) Reaches New 1-Year High - Time to Buy?

Key Points

• Avacta Group hit a new 52-week high on Friday, trading as high as GBX 85 before finishing at GBX 82.50, up from the previous close of GBX 81.
• The move came on heavy volume, with 8.6 million shares changing hands, suggesting strong investor interest in the stock.
• Avacta has a market cap of £374.14 million and trades above both its 50-day and 200-day moving averages, though the company remains unprofitable with a negative P/E ratio.

Avacta Group Plc (LON:AVCT - )'s share price reached a new 52-week high during trading on Friday . The stock traded as high as GBX 85 and last traded at GBX 82.50, with a volume of 8607747 shares changing hands. The stock had previously closed at GBX 81.

Avacta Group Stock Performance

The firm has a market capitalization of £374.14 million, a PE ratio of -4.70 and a beta of 1.12. The firm's fifty day moving average price is GBX 69.72 and its 200 day moving average price is GBX 66.83. The company has a current ratio of 0.79, a quick ratio of 4.96 and a debt-to-equity ratio of 14,168.75.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.